Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 229

1.

Both IgM and IgG Antibodies Against Polyethylene Glycol Can Alter the Biological Activity of Methoxy Polyethylene Glycol-Epoetin Beta in Mice.

Chang TC, Chen BM, Lin WW, Yu PH, Chiu YW, Chen YT, Wu JY, Cheng TL, Hwang DY, Roffler AS.

Pharmaceutics. 2019 Dec 21;12(1). pii: E15. doi: 10.3390/pharmaceutics12010015.

2.

Model-based approach for methoxy polyethylene glycol-epoetin beta drug development in paediatric patients with anaemia of chronic kidney disease [142/999 characters (incl. spaces)].

Chanu P, Schaefer F, Warady BA, Schmitt CP, Reigner B, Schnetzler G, Meyer Reigner S, Eisner M, Weichert A, Frey N.

Br J Clin Pharmacol. 2019 Nov 26. doi: 10.1111/bcp.14186. [Epub ahead of print]

PMID:
31770451
3.

Toward confirmation of the safety and efficacy of methoxy polyethylene glycol-epoetin beta in anemia treatment in patients on hemodialysis: a Macedonian experience.

Kacarska-Fotevska I, Volckova N, Ilievska K, Donev D.

Croat Med J. 2019 Oct 31;60(5):475-478. No abstract available.

4.

Cardiovascular Safety and All-Cause Mortality of Methoxy Polyethylene Glycol-Epoetin Beta and Other Erythropoiesis-Stimulating Agents in Anemia of CKD: A Randomized Noninferiority Trial.

Locatelli F, Hannedouche T, Fishbane S, Morgan Z, Oguey D, White WB.

Clin J Am Soc Nephrol. 2019 Dec 6;14(12):1701-1710. doi: 10.2215/CJN.01380219. Epub 2019 Aug 16.

PMID:
31420350
5.
6.

Time spent on erythropoietin stimulating agents administration in hemodialysis centers in Panama: a time and motion study.

Chacón-Araya M, Rey-Rodríguez D, Rodríguez De León F, Ramos-Esquivel A, Sunning T.

J Med Econ. 2019 Aug;22(8):736-741. doi: 10.1080/13696998.2019.1600527. Epub 2019 Apr 12.

PMID:
30915883
7.

SARCOSYL-PAGE: Optimized Protocols for the Separation and Immunological Detection of PEGylated Proteins.

Reichel C, Gmeiner G, Reihlen P, Thevis M, Schänzer W.

Methods Mol Biol. 2019;1855:131-149. doi: 10.1007/978-1-4939-8793-1_14.

PMID:
30426415
8.

Long-term maintenance of hemoglobin levels in hemodialysis patients treated with bi-weekly epoetin beta pegol switched from darbepoetin alfa: a single-center, 12-month observational study in Japan.

Kawai T, Kusano Y, Yamada K, Ueda C, Kawai A, Masaki T.

J Artif Organs. 2019 Jun;22(2):146-153. doi: 10.1007/s10047-018-1080-z. Epub 2018 Nov 14.

PMID:
30426250
9.

Effect of achieved hemoglobin level on renal outcome in non-dialysis chronic kidney disease (CKD) patients receiving epoetin beta pegol: MIRcerA CLinical Evidence on Renal Survival in CKD patients with renal anemia (MIRACLE-CKD Study).

Hayashi T, Uemura Y, Kumagai M, Kimpara M, Kanno H, Ohashi Y; MIRACLE-CKD Study Group.

Clin Exp Nephrol. 2019 Mar;23(3):349-361. doi: 10.1007/s10157-018-1649-0. Epub 2018 Oct 5.

10.

Epoetin Beta.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.

11.

Patterns of Erythropoiesis-Stimulating Agent Use in European Hemodialysis Patients: The Dialysis Outcomes and Practice Patterns Study.

Fuller DS, Robinson BM, Locatelli F, Pisoni RL.

Nephron. 2018;140(1):24-30. doi: 10.1159/000490202. Epub 2018 Jun 26.

12.

Role of erythropoietin and its receptor in the development of endometriosis in rats

Günal MY, Ozansoy M, Kılıç Ü, Keskin İ, Özdemir EM, Aslan İ, Eren Z, Ersavaş C, Kılıç E.

J Turk Ger Gynecol Assoc. 2019 Feb 26;20(1):41-46. doi: 10.4274/jtgga.galenos.2018.2018.0039. Epub 2018 Jun 19.

13.

Detection of erythropoiesis-stimulating agents in a single dried blood spot.

Reverter-Branchat G, Ventura R, Ezzel Din M, Mateus J, Pedro C, Segura J.

Drug Test Anal. 2018 Oct;10(10):1496-1507. doi: 10.1002/dta.2418. Epub 2018 Jul 5.

PMID:
29877055
14.

Semi-mechanistic Pharmacokinetic/Pharmacodynamic model of three pegylated rHuEPO and ior®EPOCIM in New Zealand rabbits.

Reynaldo-Fernández G, Solozábal J, Amaro D, Fernández-Sánchez EM, Rodríguez-Vera L, Bermejo M, Mangas-Sanjuan V, Troconiz IF.

Eur J Pharm Sci. 2018 Jul 30;120:123-132. doi: 10.1016/j.ejps.2018.04.047. Epub 2018 May 2.

PMID:
29729414
16.
17.

Cost-Minimisation Analysis of Erythropoiesis-Stimulating Agents in the Treatment of Anaemia in Dialysed Patients: A Pilot Study.

Darsonval A, Besson V, Cavalin C.

Pharmacoecon Open. 2017 Sep;1(3):223-229. doi: 10.1007/s41669-017-0016-5.

18.

CERA Attenuates Kidney Fibrogenesis in the db/db Mouse by Influencing the Renal Myofibroblast Generation.

Fischer C, Deininger N, Wolf G, Loeffler I.

J Clin Med. 2018 Jan 30;7(2). pii: E15. doi: 10.3390/jcm7020015.

19.

Epoetin beta pegol for treatment of anemia ameliorates deterioration of erythrocyte quality associated with chronic kidney disease.

Aizawa K, Kawasaki R, Tashiro Y, Shimonaka Y, Hirata M.

BMC Nephrol. 2018 Jan 27;19(1):19. doi: 10.1186/s12882-018-0818-4.

20.

Indexes of the erythropoietin level in the blood plasma of chronic heart failure patients with anemia.

Zahidova KK.

J Basic Clin Physiol Pharmacol. 2018 Jan 26;29(1):11-17. doi: 10.1515/jbcpp-2016-0102.

PMID:
29220885

Supplemental Content

Loading ...
Support Center